



At IDRI, our mission is to translate science into global health solutions. We develop vaccines, diagnostics, and therapeutic products that address the world's most neglected infectious diseases.

Gregory C. Ireton, PhD
Scientist II

Greg Ireton is a Scientist II at IDRI. Greg currently works on projects related to the biochemical characterization and development of IDRI's next generation vaccine for leishmaniasis. He is also focused on leprosy antigen discovery, using bioinformatics to aid in the selection and design of new candidate antigens for the development of improved rapid diagnostic tests for leprosy.

Prior to joining IDRI, Greg worked as a research technician in the Department of Microbiology at the University of Washington, focusing on the biochemical and kinetic properties of human topoisomerase I with the anti-tumor drug camptothecin. He collaborated with scientists at Washington State University working on enzymes for novel cancer therapies, and performed postgraduate work towards his thesis, "Structural studies of yeast and bacterial cytosine deaminases: directed evolution and implications for anti-cancer gene therapy."

Greg obtained his BSc with honors in Microbiology from the University of Washington in 1994. He then entered graduate studies in the Molecular and Cellular Biology Program at the University of Washington, studying protein x-ray crystallography and protein design in the laboratory of Barry Stoddard at the Fred Hutchinson Cancer Research Center. He received his PhD from the University of Washington in 2003.